NZOZ Neuro- Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy

The site conducts trials aimed at reducing the burden of heart and blood‑vessel conditions, testing new therapies to prevent events such as acute myocardial infarction, stroke, and complications of atrial fibrillation.

• Prevention strategies for acute myocardial infarction
• Stroke risk reduction in atrial fibrillation
• Management of atherosclerotic cardiovascular disease
• Outcomes in patients with heart failure
• Comparative effectiveness of novel anticoagulants

NZOZ Neuro‑Kard Ilkowski i Partnerzy supports these studies to improve cardiovascular health and long‑term survival for patients.

Research focuses on autoimmune disorders, evaluating innovative biologics and immune‑modulating agents to improve control of diseases such as myasthenia gravis and multiple sclerosis.

• New therapies for generalized myasthenia gravis
• Treatment options for ocular myasthenia gravis
• Disease‑modifying approaches in relapsing multiple sclerosis
• Strategies for progressive multiple sclerosis subtypes
• Safety profiling of emerging autoimmune disease drugs

These trials aim to enhance quality of life by reducing relapse rates and stabilizing immune activity.

Studies address chronic pain and muscle tone disorders, testing non‑opioid analgesics and injectable therapies to relieve pain and improve function.

• Non‑opioid options for chronic low back pain
• Relief of diabetic peripheral neuropathic pain
• Management of upper‑limb spasticity after stroke or brain injury
• Safety of botulinum toxin injections for spasticity
• Pain reduction in distal sensory polyneuropathy

The goal is to provide patients with safer pain relief and better mobility without reliance on opioids.

A broad program explores neurodegenerative and cognitive disorders, including Alzheimer’s disease, various forms of dementia, and early cognitive impairment, testing disease‑modifying and symptomatic agents.

• Early Alzheimer’s disease therapies targeting inflammation
• Cognitive improvement in mild cognitive impairment and early dementia
• Management of agitation in Alzheimer’s‑type dementia
• Tau‑targeted treatments for neurodegeneration
• Assessment tools for neurocognitive disorders

The neurology department at the centre leads these efforts to slow disease progression and support patient independence.

Trials focus on obesity and metabolic health, evaluating novel agents that influence weight regulation and metabolic pathways to lower cardiovascular risk.

• Efficacy of new treatments for obesity
• Impact of semaglutide on cognition in metabolic disease
• Safety profiling of emerging metabolic disease drugs
• Dual‑agonist strategies for body‑weight management
• Outcomes related to metabolic syndrome

These studies aim to provide patients with effective weight‑loss options that also improve overall metabolic health.